These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6034976)

  • 21. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Some metabolic and hormonal changes in women using long acting injectable contraceptives.
    Abdel-sayed WS; Toppozada HK; Said SA; El-sayed OK
    Alex J Pharm Sci; 1989 Mar; 3(1):29-32. PubMed ID: 12316139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contraception with injectable long-acting preparation depo-provera].
    Prilepskaia VN; Kondrikov NI; Tagieva TT
    Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.
    Albrecht BH; Schiff I; Tulchinsky D; Ryan KJ
    Am J Obstet Gynecol; 1981 Mar; 139(6):631-5. PubMed ID: 7211966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
    Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
    Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
    Jones GE; Wentz AC; Rosenwaks Z; Shoemaker J
    Am J Obstet Gynecol; 1977 Dec; 129(7):760-76. PubMed ID: 343592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of an injectable progestin-estrogen as a contraceptive.
    Scommegna A; Lee AW; Borushek S
    Am J Obstet Gynecol; 1970 Aug; 107(8):1147-55. PubMed ID: 4917852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of anti luteinizing hormone releasing factor (LH-RF) serum: immunological application and development of radioimmunoassay.
    Shiina M
    Nihon Funin Gakkai Zasshi; 1976 Oct; 21(4):12-21. PubMed ID: 12158548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy.
    Turner SJ; Mizock GB; Feldman GL
    Am J Obstet Gynecol; 1966 May; 95(2):222-7. PubMed ID: 5935707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle.
    Saunders DM; Marcus SL; Saxena BB; Beling CG; Connell EB
    Fertil Steril; 1971 May; 22(5):332-44. PubMed ID: 4102481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depo-Provera: just another contraceptive?
    Jones M
    Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medroxyprogesterone acetate and carbohydrate metabolism: measurement of glucose, insulin, and growth hormone during 6 months' time.
    Spellacy WN; McLeod AG; Buhi WC; Birk SA; McCreary SA
    Fertil Steril; 1970 Jun; 21(6):457-63. PubMed ID: 5508511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemics.
    Netw Res Triangle Park N C; 1985; 6(3):1-3. PubMed ID: 12280131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a long-acting progestin on reproductive function in female mice.
    Finn CA; Martin L
    J Endocrinol; 1978 Nov; 79(2):235-8. PubMed ID: 731148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting steroids provide new options.
    Netw Res Triangle Park N C; 1988; 9(3):1-3, 7. PubMed ID: 12315656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.